Standard BioTools Inc.

NASDAQ:LAB

Medical - Devices

Healthcare
$0.57 +3.38%

+$0.03 today

Market cap
$225.03M
Beta
1.38
P/E (TTM)
-3.5
EPS (TTM)
-$0.24
52W Low $0.79High $1.72

Volume 0.70M

Average 2.91M

LAB Deferred Revenue (Non-current)

Payments received for goods or services the company will deliver after more than one year.

Standard BioTools Inc.NASDAQ: LAB

Deferred Revenue (Non-current) · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue (non-current) falls 83.2% from a year ago

Deferred revenue (non-current) stood at $6.57M at the end of Q1 FY2026, down 83.2% from a year earlier and down 15.7% from the prior quarter. Over 3 fiscal years it compounded at -24.6% a year.

Context

  • Deferred revenue (non-current) amounted to 1.0% of total assets at the end of Q1 FY2026, down 5.7 pp from a year earlier.
  • Deferred revenue (non-current) increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether deferred revenue (non-current) keeps falling in the next quarterly balance sheet after a -83.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.57M-15.7% QoQ
Last fiscal yearDec 2025
$7.79M-80.5% YoY
Year agoMar 2025
$39.05M-83.2% since
Deferred Revenue (Non-current) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-83.2%——
1 year-80.5%——
3-year CAGR-24.6%——
5-year CAGR——
10-year CAGR——

Deferred Revenue (Non-current) history

USD · from the balance sheet

Latest · FY2025
7.79M USD
Year-over-year change
-80.5%
4-year CAGR
-24.6%

Deferred Revenue (Non-current) vs competitors

How LAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred revenue (non-current) is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -83.2% is the 2nd highest of 3, against a peer median of -43.8%.
  • Deferred revenue (non-current) amounts to 1.0% of total assets for LAB, versus a peer median of 0.0%.
LAB Competitors
Deferred Revenue (Non-current) for LAB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CTKBCytek Biosciences, Inc.Mar 2026$17.67M USD+12.4%+11.8%3.9%
LABStandard BioTools Inc.Mar 2026$6.57M USD-83.2%-24.6%1.0%
AVNSAvanos Medical, Inc.Mar 2026$0 USD——0.0%
CBLLCeriBell, Inc.Mar 2026$0 USD-100.0%—0.0%
KIDSOrthoPediatrics Corp.Mar 2026$0 USD——0.0%
VREXVarex Imaging CorporationApr 2026$0 USD——0.0%
BVSBioventus Inc.Mar 2026$0 USD——0.0%
CGEMCullinan Therapeutics, Inc.Mar 2026$0 USD——0.0%
TMCITreace Medical Concepts, Inc.Mar 2026$0 USD——0.0%
SYSo-Young International Inc.Mar 2026CN¥0 CNY——0.0%
ADCTADC Therapeutics S.A.Mar 2026$0 USD——0.0%
Peer median (excluding LAB) —-43.8%+11.8%0.0%

Competitors are the stored peer set for LAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents28.45M81.31M51.7M166.73M118.21M
Short-term Investments084.48M63.19M126.15M69.36M
Net Receivables18.32M17.28M19.66M33.61M13.43M
Inventory20.83M21.47M20.53M40.74M19.98M
Other Current Assets16K4.28M3.13M8.66M233.28M
Total Current Assets72.07M208.82M158.22M375.88M454.26M
Property, Plant & Equipment (Net)65.15M59.54M54.85M71.38M46.01M
Goodwill106.38M106.25M106.32M111.3M0
Intangible Assets27.93M12.6M1.4M28.95M0
Long-term Investments1M00025.7M
Tax Assets(1M)00038.63M
Other Non-current Assets3.69M3.11M2.29M24.83M3.15M
Total Non-current Assets203.15M181.5M164.85M236.46M113.49M
Total Assets275.21M390.31M323.07M612.34M567.75M
Account Payables10.6M7.91M9.24M12.28M5.41M
Short-term Debt6.84M2.08M59.53M05.49M
Tax Payables1.41M1.17M825K1.58M0
Deferred Revenue15.48M14.44M16.74M18.59M38.95M
Other Current Liabilities8.67M3.97M12.05M14.71M58.46M
Total Current Liabilities49.57M43.44M109.33M65.89M108.31M
Long-term Debt64.21M62.81M3.98M299K299K
Deferred Tax Liabilities4.33M1.06M841K1.08M810K
Deferred Revenue (Non-current)24.08M18.18M14.28M39.92M7.79M
Other Non-current Liabilities882K312.21M312.32M6.96M1.21M
Total Non-current Liabilities131.05M428.33M361.79M74.73M35.15M
Total Liabilities180.62M471.78M471.12M140.62M143.46M
Common Stock77K80K83K396K404K
Retained Earnings(736M)(926.1M)(1B)(1.19B)(1.26B)
Accumulated OCI(907K)(1.9M)(2.22M)1.23M(1.49M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity94.6M(81.47M)(148.05M)471.72M424.29M
Total Debt111.65M102.66M98.21M33M30.83M
Net Debt83.2M21.35M46.51M(133.73M)(87.39M)

Standard BioTools Inc.

NASDAQ:LAB

Intrinsic Alpha fair value

Locked

Current Price

$0.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.